Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry

Title: Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry

Volume: 12 Issue: 6

Author(s): Sashi Nadanaciva and Yvonne Will

Affiliation:

Keywords: Mitochondrial dysfunction, oxidative phosphorylation, organ toxicity, mitochondrial diseases, drug safety, bioenergetics, mutation, metabolomics, dyslipidemia, NSAID, water, synthesis, organic

Abstract: Drug-induced mitochondrial dysfunction is a contributor to both late-stage compound attrition and post-market drug withdrawals. This review outlines the mechanisms which lead to drug-induced mitochondrial dysfunction and discusses the tremendous advances that have been made in the development of in vitro methods to identify mitochondrial impairment. Potentially useful animal models and in vivo methods to detect drug-induced mitochondrial impairment are also discussed.

Cite this article as:

Nadanaciva Sashi and Will Yvonne, Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry, Current Drug Targets 2011; 12 (6) . https://dx.doi.org/10.2174/138945011795528985